Natural Fully Human Anti-rabies Monoclonal Antibody CBB1(Changchun BCHT)

1. Evaluate and compare the safety, tolerability, pharmacokinetics, rabies virus neutralizing antibody activity and immunogenicity characteristics of single administration of different doses of rabies monoclonal antibody CBB1 or rabies human immunoglobulin (HRIG) in healthy adults. 2. Evaluate and compare the safety, tolerability, pharmacokinetics, rabies virus neutralizing antibody activity and immunogenicity characteristics of different doses of rabies monoclonal antibody CBB1 combined with vaccine or HRIG combined with vaccine in healthy adults. 3. Compare the safety, tolerability, pharmacokinetics, rabies virus neutralizing antibody activity and immunogenicity characteristics of different doses of rabies monoclonal antibody CBB1 alone, different doses of rabies monoclonal antibody CBB1 combined with vaccine or HRIG combined with vaccine in healthy adults, further evaluate drug interactions, and explore the optimal dose for subsequent clinical trials.